Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N. Cirstea D, et al. Among authors: vallet s. Mol Cancer Ther. 2010 Apr;9(4):963-75. doi: 10.1158/1535-7163.MCT-09-0763. Epub 2010 Apr 6. Mol Cancer Ther. 2010. PMID: 20371718 Free PMC article.
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
Santo L, Vallet S, Hideshima T, Cirstea D, Ikeda H, Pozzi S, Patel K, Okawa Y, Gorgun G, Perrone G, Calabrese E, Yule M, Squires M, Ladetto M, Boccadoro M, Richardson PG, Munshi NC, Anderson KC, Raje N. Santo L, et al. Among authors: vallet s. Oncogene. 2010 Apr 22;29(16):2325-36. doi: 10.1038/onc.2009.510. Epub 2010 Jan 25. Oncogene. 2010. PMID: 20101221 Free PMC article.
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S, Cirstea D, Pozzi S, Mitsiades C, Rooney M, Kiziltepe T, Podar K, Okawa Y, Ikeda H, Carrasco R, Richardson PG, Chauhan D, Munshi NC, Sharma S, Parikh H, Chabner B, Scadden D, Anderson KC. Raje N, et al. Among authors: vallet s. Leukemia. 2009 May;23(5):961-70. doi: 10.1038/leu.2008.378. Epub 2009 Jan 8. Leukemia. 2009. PMID: 19151776
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC. Hideshima T, et al. Among authors: vallet s. Br J Haematol. 2007 Sep;138(6):783-91. doi: 10.1111/j.1365-2141.2007.06714.x. Br J Haematol. 2007. PMID: 17760810 Free article.
Fatty acid synthase is a novel therapeutic target in multiple myeloma.
Okawa Y, Hideshima T, Ikeda H, Raje N, Vallet S, Kiziltepe T, Yasui H, Enatsu S, Pozzi S, Breitkreutz I, Cirstea D, Santo L, Richardson P, Anderson KC. Okawa Y, et al. Among authors: vallet s. Br J Haematol. 2008 May;141(5):659-71. doi: 10.1111/j.1365-2141.2008.07114.x. Epub 2008 Apr 10. Br J Haematol. 2008. Retraction in: Br J Haematol. 2008 May;141(5):659. PMID: 18410446 Free PMC article. Retracted.
Emerging therapies for multiple myeloma.
Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC. Podar K, et al. Among authors: vallet s. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278. Expert Opin Emerg Drugs. 2009. PMID: 19249983 Free PMC article. Review.
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dälken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC. Ikeda H, et al. Among authors: vallet s. Clin Cancer Res. 2009 Jun 15;15(12):4028-37. doi: 10.1158/1078-0432.CCR-08-2867. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509164
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, Cristea D, Calabrese E, Gorgun G, Raje NS, Richardson P, Munshi NC, Lannutti BJ, Puri KD, Giese NA, Anderson KC. Ikeda H, et al. Among authors: vallet s. Blood. 2010 Sep 2;116(9):1460-8. doi: 10.1182/blood-2009-06-222943. Epub 2010 May 26. Blood. 2010. PMID: 20505158 Free PMC article.
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig S, Vallet S, Pozzi S, Patel K, Unitt C, Squires M, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje N. Santo L, et al. Among authors: vallet s. Clin Cancer Res. 2011 May 15;17(10):3259-71. doi: 10.1158/1078-0432.CCR-10-3012. Epub 2011 Mar 23. Clin Cancer Res. 2011. PMID: 21430070 Free PMC article.
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC. Yasui H, et al. Among authors: vallet s. Br J Haematol. 2007 Feb;136(3):414-23. doi: 10.1111/j.1365-2141.2006.06443.x. Epub 2006 Dec 14. Br J Haematol. 2007. PMID: 17173546 Free article.
183 results